Povetacicept (BAFF/APRIL)

Overview

Povetacicept is a recombinant fusion protein being evaluated in patients with IgA nephropathy and primary membranous nephropathy. The novel investigational treatment is also in development for multiple, serious B cell-mediated diseases, including other autoimmune kidney diseases and autoimmune cytopenias. Povetacicept targets both the B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) cytokines, which play key roles in the activation, differentiation, and/or survival of B cells, T cells, and innate immune cells. This dual mechanism has the potential to address the pathogenesis of multiple autoimmune diseases.

In pre-clinical studies, povetacicept demonstrated the potential to provide higher binding affinity and greater potency than other treatments targeting APRIL and/or BAFF, suggesting its potential to be a best-in-class treatment option.

In 2025, Zai Lab obtained an exclusive license for the development and commercialization of povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory) from Vertex Pharmaceuticals Incorporated.